IFRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient trader: price is weak (bearish trend + negative MACD), sitting near support with no proprietary buy signals today.", "Upside is largely catalyst-driven (INF904 development), but near-term financing/dilution risk at this low price is a major overhang per recent analyst commentary.", "Options positioning looks bullish by open-interest skew, but volume is extremely thin (calls=8, puts=0), so it\u2019s not a strong, reliable sentiment confirmation."]
["Trend: Bearish (SMA_200 > SMA_20 > SMA_5), indicating persistent downside momentum across short/medium/long windows.", "Momentum: MACD histogram -0.0102 and negatively expanding \u2192 bearish momentum is strengthening, not stabilizing.", "RSI(6)=32.26: approaching oversold but still not showing a clear reversal signal; \u201ccheap\u201d can stay cheap without a catalyst.", "Key levels: Current pre-market ~0.8568 is just above S1=0.839 (near-term support). A clean break below S1 opens room toward S2=0.778. Resistance to reclaim is Pivot=0.938, then R1=1.038.", "Pattern-based outlook (similar candlesticks): skewed slightly negative (50% chance to -2.74% next day; -0.82% next week; -3.08% next month), reinforcing near-term caution.", "Intellectia Proprietary Trading Signals: No signal on given stock today. (- AI Stock Picker: no signal on given stock today.) (- SwingMax: No signal on given stock recently.)"]
and holds, a technical bounce toward ~1.04 (R
becomes more plausible."]
explicitly flags likely future financing that could be notably dilutive at current valuation.", "No fresh news in the last week to act as an immediate upside catalyst in pre-market.", "Micro-cap biotech dynamics: sentiment can flip quickly, but without a near-term catalyst, downside drift is common."]
["Latest quarter: 2025/Q3.", "Revenue: 23,830, down -80.75% YoY (sharp contraction; not currently a revenue-supported story).", "Net income: -12.26M (loss), down -29.73% YoY (still meaningfully unprofitable).", "EPS: -0.18, down -40.00% YoY (loss per share widened).", "Overall: financials reinforce that IFRX is primarily a pipeline/catalyst trade; without near-term catalysts, funding risk tends to dominate price action."]
["Recent trend: Strong upgrades/target raises in Nov 2025 after Phase 2a INF904 data (e.g., targets raised to $7\u2013$24 by multiple firms), followed by a notable Dec 2025 downgrade from Leerink to Market Perform with target cut to $2 (from $5).", "Wall Street pros (bull case): INF904 seen by several analysts as potentially best-in-class oral C5aR therapy with attractive HS opportunity and encouraging early efficacy/safety.", "Wall Street cons (bear case): Even with positive data, dilution/financing risk is front and center; at the current depressed price, new capital could significantly pressure shares.", "Net takeaway: Street is split\u2014science optimism vs. capital structure risk\u2014while the tape/technicals currently align more with the cautious camp."]
